ALKEM · Healthcare
Alkem Laboratories Ltd. reported revenue of ₹3,440 cr for July to September 2023, — on the year and +15.9% on the quarter.
Operating profit (EBITDA) was ₹747 cr, a margin of 21.7%, — on the year and +861 bps on the quarter.
Net profit was ₹615 cr, — on the year and +113.5% on the quarter, with earnings per share of ₹51.90.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Headline vs core profit, Exceptional items that recur, Operating margin on the year, Depreciation falling, Finance cost rising, Swing to loss or profit, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,440 cr | ₹3,324 cr | ₹2,936 cr | ₹3,032 cr | ₹3,415 cr | ₹3,374 cr | ₹3,144 cr | ₹3,371 cr | ₹4,001 cr | ₹3,737 cr | ₹3,603 cr | ₹3,740 cr |
| YoY | — | — | — | +2% | −1% | +2% | +7% | +11% | +17% | +11% | +15% | +11% |
| EBITDA margin | 21.7% | 21.3% | 13.7% | 20.1% | 22.0% | 22.5% | 12.4% | 21.9% | 23.0% | 22.2% | 14.3% | 20.5% |
| Other income, % of PBT | 1% | 6% | 21% | 19% | 17% | 13% | 37% | 19% | 12% | 12% | 15% | 20% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 5% | 8% | 17% | 11% | 10% | 12% | 18% | 13% | 13% | 16% | 40% | 32% |
| Net profit | ₹615 cr | ₹604 cr | ₹304 cr | ₹550 cr | ₹702 cr | ₹641 cr | ₹322 cr | ₹668 cr | ₹779 cr | ₹653 cr | ₹251 cr | ₹521 cr |
| YoY | — | — | — | +91% | +14% | +6% | +6% | +21% | +11% | +2% | −22% | −22% |
| Core profit YoY | — | — | — | +74% | +1% | +4% | −14% | +25% | +23% | +8% | +43% | −0% |
| EPS | ₹51.90 | ₹49.76 | ₹24.55 | ₹45.60 | ₹57.60 | ₹52.34 | ₹25.58 | ₹55.56 | ₹63.99 | ₹53.19 | ₹19.78 | ₹43.49 |
| Flags | · | · | · | 1 | ✓ | ✓ | 2 | ✓ | ✓ | ✓ | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Alkem Laboratories Ltd. reported revenue of ₹3,440 cr (— on the year) and net profit of ₹615 cr (— on the year) for July to September 2023.
None of the 2 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.